# **Learning Outcomes (Slide 2)**

You must be able to:

- Define what makes a substance a **neurotransmitter** (synthesis, storage, release, inactivation)
    
- Explain **inactivation methods** and how **receptor variety** expands function
    
- Recall **normal functions** of key neurotransmitters
    
- Illustrate **disease links** using named examples
    
- Give examples of **therapeutic drugs** modifying synaptic transmission  
    

---

# âš¡ **2. What is Synaptic Transmission? (Slide 3)**

- Mechanism by which cells communicate **across a synaptic cleft (~20 nm)**
    
- Two main types: **electrical** and **chemical synapses**  
    

---

# ğŸ”Œ **3. Electrical Synapses (Slide 4)**

**Diagram on slide 4** shows:

- Very close membranes
    
- Low-resistance pathway
    
- Formed by **gap junctions** (connexons made of connexins)
    
- Bidirectional signalling  
    

Useful where **speed** is essential (e.g., brainstem reflexes).

---

# ğŸ§ª **4. Chemical Synapses (Slide 5)**

- Neurotransmitter bridges pre â†’ post neuron
    
- **Unidirectional**
    
- Composed of 5â€“7 steps in NT release (each modifiable by drugs/toxins)  
    

These steps allow numerous drug targets (e.g., vesicle fusion, reuptake).

---

# ğŸ§¬ **5. What Is a Neurotransmitter? (Slide 6)**

Must meet **all** four criteria:

1. **Synthesised** in presynaptic neuron
    
2. **Stored** presynaptically (in vesicles)
    
3. **Released** by depolarisation + CaÂ²âº
    
4. **Inactivated** (reuptake, degradation, diffusion)  
    

---

# ğŸ’¡ **6. NT Release Mechanism (Diagram, Slide 7)**

Slide 7 (Boron & Boulpaep figure) shows:

- AP â†’ CaÂ²âº entry â†’ vesicle fusion â†’ NT release
    
- NT diffuses to **ionotropic or metabotropic receptors**
    
- Inactivation: reuptake, enzymes  
    

---

# âš™ï¸ **7. Post-Synaptic Receptors (Slide 8)**

Slide diagram compares ionotropic vs metabotropic ACh receptors.

### **Ionotropic (fast)**

- Ligand-gated ion channels (e.g., **nicotinic AChR**)
    
- Direct cation influx â†’ depolarisation â†’ contraction
    

### **Metabotropic (slow)**

- GPCRs (e.g., **muscarinic AChR**)
    
- G-protein â†’ 2nd messenger â†’ Kâº efflux â†’ â†“ heart rate  
    

**Clinical significance:** same NT (ACh) produces **different outcomes depending on receptor subtype**.

---

# **8. Classes of Neurotransmitters (Slides 9â€“10)**

The table on slides 9â€“10 lists:

### **Amino acids**

- Glutamate
    
- Aspartate
    
- GABA
    
- Glycine
    

### **Amines**

- Acetylcholine
    
- Dopamine
    
- Adrenaline
    
- Noradrenaline
    
- Serotonin
    

### **Peptides**

- Endorphins
    
- Enkephalins
    
- Substance P
    
- Dynorphin  
    

---

# ğŸ§ª **9. AMINO ACID NEUROTRANSMITTERS**

---

# **9A. Glutamate (Slides 11â€“12)**

Slide 11 key facts:

- **Main fast excitatory NT** in the CNS
    
- Acts on **ionotropic receptors**:
    
    - **NMDA** â†’ CaÂ²âº
        
    - **AMPA** â†’ cations
        
    - **Kainate** â†’ Naâº & Kâº
        
- Reuptake by **EAAT** transporters  
    

### (Dys)function (Slide 12)

**Pain:**

- AÎ´ & C fibres synapse in dorsal horn â†’ glutamate activates ascending pain pathways
    
- Opioids **augment glutamate signalling pre- and post-synaptically**, enhancing analgesia
    

**Migraine:**

- Glutamate involved in **cortical spreading depression**
    
- Visual aura explained by prolonged glutamatergic activity  
    

---

# **9B. GABA (Slides 13â€“14)**

Slide 13:

- ~50% of inhibitory synapses use GABA
    
- Activates **Clâ» channels**:
    
    - **GABA_A, GABA_C** (ionotropic)
        
    - **GABA_B** (metabotropic)
        
- Reuptake via presynaptic terminal  
    

### (Dys)function (Slide 14)

**Anxiety disorders:**

- Benzodiazepines enhance GABA_A receptor function â†’ â†‘ inhibition
    

**Alcohol use disorder:**

- Chronic excess alcohol alters GABAergic transmission â†’ tolerance, withdrawal  
    

---

# **9C. Glycine (Slides 15â€“16)**

Slide 15:

- Remaining half of inhibitory CNS synapses
    
- Ligand-gated Clâ» channels (**GlyR**)
    
- **Co-agonist of NMDA** (required for NMDA activation)
    
- Pre-synaptic reuptake  
    

### (Dys)function â†’ **Tetanus** (Slide 16)

- Clostridium tetani toxin blocks **glycine release**
    
- Causes loss of inhibition â†’ rigidity, hyperreflexia, â€œlockjawâ€
    
- Severe cases â†’ epileptiform fits
    
- Treat with antitoxin + benzodiazepines  
    

The painting on slide 16 (Charles Bell) illustrates tetanic spasms.

---

# ğŸ”µ **10. AMINES**

---

# **10A. Dopamine (Slide 18)**

- Involved in **reward, addiction, movement**
    
- Acts on **D1 (excitatory)** & **D2 (inhibitory)** metabotropic receptors  
    

### (Dys)function

- Recreational drugs â†’ acute â†‘ dopamine â†’ chronic â†“ dopaminergic activity
    
- **Parkinsonâ€™s disease** â†’ degeneration of dopaminergic neurons â†’ bradykinesia  
    

---

# **10B. Noradrenaline (Slide 19)**

- Excitatory NT for **wakefulness, attention**
    
- Acts on Î± (excitatory) and Î² (inhibitory) metabotropic receptors
    
- Reuptake via NET transporters  
    

### (Dys)function

- Depression: **hypofunction of NA system**
    
- **Reuptake inhibitors** â†‘ synaptic NA â†’ antidepressant effect  
    

---

# **10C. Serotonin (Slide 20)**

- Regulates **wakefulness, mood, sleep**
    
- Mostly metabotropic receptors
    
- Reuptake via SERT  
    

### (Dys)function

- Depression
    
- **SSRIs** block reuptake â†’ â†‘ 5-HT action
    
- Psychedelics (psilocybin, LSD) affect 5-HT networks (slide notes involvement with default mode network)  
    

---

# **10D. Acetylcholine (Slide 21)**

- Excitatory NT in CNS, PNS, NMJ
    
- Acts on:
    
    - **Nicotinic AChR (ionotropic)**
        
    - **Muscarinic AChR (metabotropic)**
        
- Termination via **acetylcholinesterase**  
    

### (Dys)function â€” **Myasthenia Gravis**

- Autoantibodies against **nAChR** â†’ fewer receptors â†’ fatigable weakness
    
- AChE inhibitors improve symptoms
    
- BUT same inhibitors = **toxins** (organophosphate insecticides, nerve gases)  
    

---

# ğŸ”¶ **11. PEPTIDES (Slide 23)**

### Endorphins & Enkephalins

- Endogenous ligands of **opioid receptors**
    
- Exogenous opioids (morphine, heroin, methadone) â†’ receptor **downregulation**
    
- Leads to **tolerance** and escalating intake  
    

---

# ğŸ“˜ **12. Lecture Summary Slide (Slide 25)**

Key messages listed:

- NTs enable chemical synaptic communication
    
- Must meet synthesisâ€“storageâ€“releaseâ€“inactivation criteria
    
- NT classes: amino acids, amines, peptides
    
- Receptors: ionotropic vs metabotropic
    
- Diseases arise from NT dysfunction (e.g., MG, depression, Parkinsonâ€™s, tetanus)
    
- Drugs can modify synaptic transmission  
    

---

# ğŸ”¥ **HIGH-YIELD EXAM SECTION â€” Ultra-Condensed Revision**

### **Criteria for a Neurotransmitter**

1. Synthesised presynaptically
    
2. Stored in vesicles
    
3. Released by CaÂ²âº-dependent exocytosis
    
4. Inactivated (reuptake or degradation)
    

---

# **Ionotropic vs Metabotropic**

ğŸ”¹ Ionotropic = FAST (nAChR, GABA_A, AMPA, NMDA)  
ğŸ”¹ Metabotropic = SLOW (mAChR, GABA_B, D1/D2, 5-HT receptors)

---

# **Key NT Functions**

- **Glutamate** â†’ main excitatory NT (NMDA/AMPA)
    
- **GABA** â†’ main inhibitory NT (GABA_A: Clâ»)
    
- **Glycine** â†’ inhibitory in spinal cord/brainstem
    
- **Dopamine** â†’ reward + movement
    
- **Noradrenaline** â†’ attention + wakefulness
    
- **Serotonin** â†’ mood + sleep
    
- **ACh** â†’ NMJ + autonomic ganglia
    
- **Peptides** â†’ neuromodulation, pain, stress
    

---

# **NT Pathology to Know Cold**

- **Myasthenia gravis** â†’ antibodies to nAChR
    
- **Depression** â†’ â†“ NA & â†“ 5-HT (treat with reuptake inhibitors)
    
- **Parkinsonâ€™s** â†’ loss of dopaminergic neurons
    
- **Tetanus** â†’ loss of glycine release â†’ disinhibition
    
- **Anxiety** â†’ reduced GABA_A function
    
- **Migraine** â†’ glutamate & cortical spreading depression
    

---

# **Drug Mechanisms (High Yield)**

- **Benzodiazepines** â†’ â†‘ GABA_A
    
- **SSRIs** â†’ block 5-HT reuptake
    
- **NARIs** â†’ block NA reuptake
    
- **AChE inhibitors** â†’ â†‘ ACh (therapy or toxicity)
    
- **Opioids** â†’ activate opioid receptors â†’ tolerance